Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 9/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | USP5 | P45974 | 3/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | USP3 | Q9Y6I4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155440 | 0.91 | USP5 (0.39) | DRD2TP53LMNAMAPTUSP5 | |
| SCHEMBL2156546 | 0.90 | USP5 (0.38) | CCR1LMNAMAPTL3MBTL1USP5 | |
| SCHEMBL2155370 | 0.90 | CCR1 (0.44) | MCHR1CCR1USP5 | |
| SCHEMBL2156142 | 0.89 | DRD2 (0.42) | DRD2USP5MMP3CTSC | |
| SCHEMBL2156040 | 0.84 | KDM4E (0.42) | DRD2MAPTHDAC6 | |
| SCHEMBL16501802 | 0.84 | DRD2 (0.40) | DRD2MCHR1CCR1TP53LMNA | |
| SCHEMBL2155367 | 0.81 | DRD2 (0.38) | DRD2MCHR1CCR1TP53LMNA | |
| SCHEMBL5519230 | 0.81 | DRD2 (0.38) | DRD2MCHR1CCR1TP53LMNA | |
| SCHEMBL2155744 | 0.80 | USP5 (0.40) | DRD2CCR1LMNAMAPTUSP5 | |
| SCHEMBL2155363 | 0.79 | PANK3 (0.38) | DRD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | claimed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | claimed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | claimed |
| EP-1828160-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-09-05 | — | — | EP | claimed |
| WO-2006067114-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-06-29 | — | — | WO | claimed |
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | disclosed |
| EP-1828160-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006067114-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | GLS2, SRM, GLS | DRD2 4576/4885MCHR1 4784/4885CCR1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.